The treatment of AML: Current status and novel approaches

被引：16

作者：

Burnett, AK ^{[1
]}

机构：

[1] Cardiff Univ, Sch Med, Cardiff CF14 4XN, S Glam, Wales

来源：

HEMATOLOGY | 2005年 / 10卷

关键词：

D O I：

10.1080/10245330512331389773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：50 / 53

页数：4

共 30 条

[1] Prognostic index for adult patients with acute myeloid leukemia in first relapse [J].

Breems, DA ;

Van Putten, WLJ ;

Huijgens, PC ;

Ossenkoppele, GJ ;

Verhoef, GEG ;

Verdonck, LF ;

Vellenga, E ;

De Greef, G ;

Jacky, E ;

Van der Lelie, J ;

Boogaerts, MA ;

Löwenberg, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1969-1978

[2]

Burnett AK, 2004, BLOOD, V104, p179A

[3] A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. [J].

Burnett, AK ;

Russell, N ;

Kell, JW ;

Milligan, D ;

Culligan, D .

BLOOD, 2004, 104 (11) :248A-248A

[4]

Burnett AK, 2002, BLOOD, V100, p155A

[5] Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial [J].

Burnett, AK ;

Goldstone, AH ;

Stevens, RMF ;

Hann, IM ;

Rees, JKH ;

Gray, RG ;

Wheatley, K .

LANCET, 1998, 351 (9104) :700-708

[6] The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial [J].

Burnett, AK ;

Wheatley, K ;

Goldstone, AH ;

Stevens, RF ;

Hann, IM ;

Rees, JHK ;

Harrison, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :385-400

[7]

Burnett Alan K, 2002, Rev Clin Exp Hematol, V6, P26

[8] Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].

Cassileth, PA ;

Harrington, DP ;

Appelbaum, FR ;

Lazarus, HM ;

Rowe, JM ;

Paietta, E ;

Willman, C ;

Hurd, DD ;

Bennett, JM ;

Blume, KG ;

Head, DR ;

Wiernik, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656

[9] SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes [J].

Giles, FJ ;

Stopeck, AT ;

Silverman, LR ;

Lancet, JE ;

Cooper, MA ;

Hannah, AK ;

Cherrington, JM ;

O'Farrell, AM ;

Yuen, HA ;

Louie, SG ;

Hong, W ;

Cortes, JE ;

Verstovsek, S ;

Albitar, M ;

O'Brien, SM ;

Kantarjian, HM ;

Karp, JE .

BLOOD, 2003, 102 (03) :795-801

[10]

Giles FJ, 2001, CANCER-AM CANCER SOC, V92, P406, DOI 10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO

← 1 2 3 →